Issue Information ‐ Instructions to Authors
25 October 2018
25 October 2018
25 October 2018
Shi Liu, Bin Zhou, Juan D. Valdes, Jian Sun, Haitao Guo – 25 October 2018 – Chronic hepatitis B infection is one of the major etiological causes of liver failure, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. This condition cannot be completely cured by currently available drugs due to the persistent existence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), the bona fide transcription template for HBV RNAs, in infected hepatocytes.
25 October 2018
Hynek Mergental, Barnaby T. F. Stephenson, Richard W. Laing, Amanda J. Kirkham, Desley A. H. Neil, Lorraine L. Wallace, Yuri L. Boteon, Jeannette Widmer, Ricky H. Bhogal, M. Thamara P. R. Perera, Amanda Smith, Gary M. Reynolds, Christina Yap, Stefan G. Hübscher, Darius F. Mirza, Simon C. Afford – 25 October 2018 – Increased use of high‐risk allografts is critical to meet the demand for liver transplantation. We aimed to identify criteria predicting viability of organs, currently declined for clinical transplantation, using functional assessment during normothermic machine perfusion (NMP).
Shi Liu, Bin Zhou, Juan D. Valdes, Jian Sun, Haitao Guo – 25 October 2018 – Chronic hepatitis B infection is one of the major etiological causes of liver failure, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. This condition cannot be completely cured by currently available drugs due to the persistent existence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), the bona fide transcription template for HBV RNAs, in infected hepatocytes.
25 October 2018
25 October 2018
Sanjay Goja, Sanjay Kumar Yadav, Arvinder Singh Soin – 25 October 2018 – For equipoising donor safety and optimal recipient outcomes, we adopted an algorithmic “triangle of safety” approach to retrieve 3 types of right lobe liver grafts (RLGs), namely, the modified extended right lobe graft (MERLG), the partial right lobe graft (PRLG), and the modified right lobe graft (MRLG). Reconstruction to achieve a single wide anterior sector outflow was ensured in all patients.
This webinar focuses on reviewing the highlights of the revised AASLD Clinical Practice Guidelines for HBV infection in the first talk. The second presentation addresses a key area of controversy, namely the role of antiviral therapy in patients during the immunotolerant phase of chronic HBV infection.Naga P. Chalasani (Moderator) Naga P. Chalasani, MD, FAASLD currently serves as David W. Crabb Professor of Medicine and Interim Chair of the Department of Medicine at Indiana University School of Medicine.